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ABSTRACT
Because of the threat of misuse of nerve agents as terroristic weapons by the terrorists, an
immediate need is felt for the preparation of antidotes on large-scale basis.  HI-6 (dichloride and
dimethanesulphonate) salt are the most promising acetylcholinesterase reactivators used as
causal antidotes in nerve agents intoxication. In this study, rapid and large-scale preparation
of oxime HI-6, the most promising reactivator has been described.
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1 . INTRODUCTION
Organophosphorus compounds are available
worldwide and many of these belong to the  biologically
active compounds1-5. Biological effect of several
of them is based on the inhibition of the enzyme
acetylcholinesterase (AChE; EC 3.1.1.7)1,5,6-9.
The most extended organophosphorus AChE inhibitors
are the pesticides. Earlier also, nerve agents
were wide-spread group of these substances which
were incorporated into the armament of many
armies5,10.
Although, the development and storage of these
compounds are currently prohibited due to their
potential misuse by terrorists. The misuse of these
agents had happened in Tokyo, in 1995. Owing to
the release of sarin nerve agent, 12 people died
and thousands were intoxicated11.
To overcome the threat of the nerve agent,
new antidotes against nerve agents have been
developed12-16. Among them, oxime HI-6 seems to
be the number one due to its promising and relatively
broad-spectrum reactivation potency17,18. Although
the synthesis of  oxime HI-6 was patented several
times, the common synthesis which could be used
for rapid production of pure compound on large-
scale was not published yet19-21. Because of the
commercial importance of two salts of  oxime HI-6
 dichloride (formerly preferred salt of HI-6) and
dimethanesulphonate (DMS; currently preferred salt
of HI-6), their synthesis have been described  which
can be prepared in the laboratory on a large-scale.
2 . SYNTHESIS
General approach how to prepare bisquaternary
unsymmetrical (like HI-6) AChE reactivators was
SHORT COMMUNICATION
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described many times12-16,19-24. It depends mainly
on the reactivity of the appropriate alkylating agent
used for the quaternisation. For HI-6, bis-(chloromethyl)
ether (purchased from Hi-chem, Czech Republic)
is used as the alkylating chain. Two possible ways
for the preparation of HI-6 (Fig. 1) are: (i) from
the isonicotinamide and (ii) from the 2-hydroxy-
iminopyridine. In this study, a preferred way to
prepare HI-6 via the monoquaternary oxime intermediate,
has been described.
2.1 Analysis of Intermediates and Products
Purity of both the intermediates and the products
was tested by determining the melting point (Boetius
block and were uncorrected); TLC [(Kieselgel Merck;
mobile phase n-BuOH/CH
3
COOH / H
2
O (5:1:2)];
detection of UV 254 (Dragendorff·s reagent); HPLC
[Column 250 mm x 4 mm I.D. Lichrospher 60 RP-
select B (5 mm); Merck, Darmstadt, Germany];
mobile phase - 24 per cent acetonitrile and 76 per
cent water, containing  octane-1-sulphonic acid
sodium salt (8 mM),  tetramethylammonium chloride
(2 mM); isocratic delivery at a flow rate of 1 ml/min,
UV detection at 277 nm; 25 °C) and NMR (Varian
Gemini 300; 300 MHz)25,26.
In Scheme 1, structures of all compounds (parent
compounds, intermediates, byproducts, and final products)
are shown occurring within the synthesis of HI-6.
2.1.1 Preparation of 2-Hydroxyiminomethyl-
1-(Chlormethoxymethyl) Pyridinium
Chloride
Pyridine-2-aldoxime (183.5 g, 1.5 mol) was
dissolved in chloroform (1000 ml)and heated to
50 °C. Then, bis(chloromethyl)ether (172.7 g,  1.5 mol)
were added. Reaction mixture was stirred for 4 h.
The reaction mixture was allowed to cool to the
laboratory temperature, brownish compound was
separated, and then stirred with ethanol. Subsequently,
yellowish compound was separated and rinsed twice
by diethylether. White-grey product (146 g, yield
41 %) was collected (mp 146150 °C; TLC:
R
f
 = 0.5; HPLC: R
t
 = 8.07 min; 1H NMR: (D
2
O):
was not done because of low stability of the
monoquaternary salt) and without further purification
subjected to other synthetic step.
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Figure 1. Scheme for the preparation of the HI-6.
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dissolved in isopropanole, purified with activated
carbon and crystalised. 80.14 g (yield 34.5 %) of
the resulted compound was collected (m.p. 138-
147 °C; TLC: R
f
 = 0.3; HPLC: R
t
 = 10.30 min; 1H
NMR (D
2
O): 6.35 (s, 2H, CH
2
); 6.50 (s, 2H, CH
2
);
8.17 (dd, 1H, Ph-H, 3JHH = 6.3 Hz, 3JHH =
7.8 Hz); 8.51 (d, 2H, Ph-H, 3JHH = 6.3 Hz); 8.53
(s, 1H, CH=N); 8.75 (m, 2H, Ph-H); 9.17 (d, 1H,
Ph-H, 3JHH = 6.3 Hz); 9.24 (d, 2H, Ph-H, 3JHH
= 6.6 Hz) ppm. NOH a CONH
2
 signals were not
found in the spectra).
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Compound Abbreviation Formula Mol Wt Melting point  (°C) 
Bis-(chloromethyl)ether BCME C2H4Cl2O 114.96 - * 
Pyridine-2-aldoxime P2A C6H6N2O 122.12 105 - 107 
Monoquaternary P2A Mono P2A C8H10Cl2N2O2 237.08 146 - 150 
Isonicotinamide INA C6H6N2O 122.12 156 - 158 
HI-6 dichloride HI6 2Cl C14H16Cl2N4O3 359.21 150 - 152 
HI-6 dimethanesulphonate HI6 DMS C16H22N4O9S2 478.50 173 - 175 
Bisquaternary P2A Bis-P2A C14H16Cl2N4O3 359.21 199 - 201 
Bisquaternary INA Bis-INA C14H16Cl2N4O3 359.21 234 - 236 
* liquid at room temperature 
2.1.2 Preparation of 1-(2-(Hydroxyimino-
methyl) Pyridinium)-3-(4-Carbamoyl-
pyridinium)-2-Oxapropane Dichloride
(HI-6 Cl)
 Solution of 2-hydroxyiminomethyl-1-chlormethoxy-
methylpyridinium chloride (146.0 g, 0.616 mol) in
1200 ml of dry dimethylformamide was added a
solution of (75.2 g) isonicotinamide. The reaction
mixture was stirred for four hours at 50 °C under
argone atmosphere. Grey product was filtered, rinsed
by ethanol and diethylether. Then, the product was
Scheme 1: Structures and basic physical properties of parent substances, byproducts, intermediates, and final products, which
could be found as byproducts of synthesis of HI-625,26.
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2.1.3 Preparation of 1-(2-(Hydroxyimino-
methyl) Pyridinium)-3-(4-Carbamoyl-
pyridinium)-2-Oxapropane Dimethane-
sulphonate (HI-6 DMS)
Column with,  DOWEX (136 g, 2 x 8, 100/200,
Cl-) in OH cycle was rinsed with  methanesulfonic
acid (1300 ml) solution (1 M). Subsequently, the
column was rinsed with water to get neutral pH.
HI-6 dichloride (27 g) in distilled water (205 ml)
were tracked into the column. Yellow solution of
HI-6 DMS was collected in twenty fractions. All
fractions, except the first three, were put together
and evaporated to one fifth and cooled to room
temperature. Then, ethanol was added into the
solution and put into the refrigerator for crystalisation.
After 2 h, arisen crystals (29.50 g; yield 83 %)
were collected, washed by diethylether and dried
in oven (50 °C) (m.p. 165-167 °C; TLC:  R
f
 = 0.4;
HPLC: R
t
 = 10.30 min; 1H  NMR (D2O): 2.25
(s, 6H, CH
3
SO
3
-); 6.35 (s, 2H, CH
2
); 6.50 (s, 2H,
CH
2
); 8.17 (dd, 1H, Ph-H, 3JHH = 6.3 Hz, 3JHH
= 7.8 Hz); 8.51 (d, 2H, Ph-H, 3JHH = 6.3 Hz);
8.53 (s, 1H, CH=N); 8.75 (m, 2H, Ph-H); 9.17 (d,
1H, Ph-H, 3JHH = 6.3 Hz); 9.24 (d, 2H, Ph-H,
3JHH = 6.6 Hz) ppm. NOH a CONH
2
 signals were
not found in the spectra).
3 . DISCUSSION
Development of the AChE reactivators is very
important task12-16. For nerve agents, HI-6 seems
to be the number one17,l8. However, for cases of
tabun and pesticides-intoxications, new derivatives
are still designed and synthetised1,2,27,28.  Till today,
only six reactivatorspralidoxime, obidoxime, tri-
medoxime, methoxime (MMB-4), HI-6, and diethyxime
are used as antidotes in several armies worldwide29.
Moreover, introducing another one new and promising,
is now unrealistic, and if there will be any candidate,
it will be very expensive.
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